Pfizer (PFE 0.77%) made a fortune thanks to its work in the COVID-19 market. In 2022, it became the first company in the ...

Bispecific anti-PD1/VEGF remains one of the hottest topics in the oncology field. Click here for a detailed analysis.

Pfizer Inc. has secured an exclusive global licensing agreement with 3SBio, Inc., a leading Chinese biopharma, for SSGJ-707.

Pfizer has struck a high-stakes deal with 3SBio to license SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, outside ...

Pfizer shares climbed Tuesday after two punchy headlines hit the wire. FDA advisors are considering COVID-19 vaccines for ...

The pharma giant entered an exclusive agreement with the Chinese biotech to gain rights to a cancer bispecific drug candidate.

Pfizer closes a deal on a new Cancer drug. The stock is pacing for 4th day of gains. The Investment Committee debate the ...

The deal comes three months after Pfizer inked a PD-1/VEGF partnership with Summit Therapeutics, leading BMO Capital Markets ...

Pfizer will pay China’s 3SBio $1.25 billion up front to access a cancer drug that could rival Akeso and Summit’s closely ...

3SBio will receive an upfront payment of $1.25B and is eligible to receive milestone payments associated with certain development, regulatory and commercial milestones up to $4.8B as well as tiered ...

U.S. drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc , paying $1.25 billion ...

Pfizer will pay $1.25 billion upfront to license an experimental cancer drug out of China, in a deal that underscores ...